Jynarque

symptomatic euvolemic Hyponatremia, symptomatic hypervolemic Hyponatremia, Polycystic Kidney, Autosomal Dominant

Treatment

4 FDA approvals

8 Active Studies for Jynarque

Treatment for

symptomatic euvolemic Hyponatremia

What is Jynarque

TolvaptanThe Generic name of this drug

Treatment SummaryTolvaptan is a medication used to treat low sodium levels in the blood. This condition is called hyponatremia, and it can be caused by heart failure, liver disease, or a hormone imbalance. Tolvaptan was approved by the FDA in 2009.

Samscais the brand name

image of different drug pills on a surface

Jynarque Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Samsca

Tolvaptan

2009

Approved as Treatment by the FDA

Tolvaptan, also called Samsca, is approved by the FDA for 4 uses including Autosomal Dominant Polycystic Kidney Disease （ADPKD) and symptomatic euvolemic Hyponatremia .

Autosomal Dominant Polycystic Kidney Disease （ADPKD)

Helps manage Autosomal Dominant Polycystic Kidney Disease （ADPKD)

symptomatic euvolemic Hyponatremia

symptomatic hypervolemic Hyponatremia

Polycystic Kidney, Autosomal Dominant

Helps manage Autosomal Dominant Polycystic Kidney Disease （ADPKD)

Effectiveness

How Jynarque Affects PatientsTaking tolvaptan leads to an increase in the amount of urine and fluids consumed, resulting in a loss of fluids from the body. This drug increases the levels of sodium and osmolality in the blood 4-8 hours after use, and these effects last up to 24 hours. As the dosage increases, so do the changes in sodium and osmolality levels. Additionally, 4 hours after taking tolvaptan, urine osmolality decreases and free water clearance increases. Tolvaptan binds to V2 receptors in the body 29 times more than it binds to V1a receptors, and does not bind

How Jynarque works in the bodyTolvaptan is a medication that blocks the action of a hormone called vasopressin. When vasopressin binds to certain receptor cells in the body, it causes cells in the kidneys to absorb more water. Tolvaptan prevents this process from happening, increasing urine volume and reducing intravascular volume. This is especially helpful for heart failure patients, who tend to have higher levels of vasopressin.

When to interrupt dosage

The suggested dose of Jynarque is contingent upon the diagnosed circumstance, such as symptomatic hypervolemic Hyponatremia, symptomatic euvolemic Hyponatremia and Polycystic Kidney, Autosomal Dominant. The magnitude of dosage is dependent upon the method of administration provided in the table below.

Condition

Dosage

Administration

Polycystic Kidney, Autosomal Dominant

, 15.0 mg, 30.0 mg, 60.0 mg, 90.0 mg, 120.0 mg, 45.0 mg, 7.5 mg

Tablet - Oral, , Tablet, Oral

symptomatic euvolemic Hyponatremia

, 15.0 mg, 30.0 mg, 60.0 mg, 90.0 mg, 120.0 mg, 45.0 mg, 7.5 mg

Tablet - Oral, , Tablet, Oral

symptomatic hypervolemic Hyponatremia

, 15.0 mg, 30.0 mg, 60.0 mg, 90.0 mg, 120.0 mg, 45.0 mg, 7.5 mg

Tablet - Oral, , Tablet, Oral

Warnings

There are 20 known major drug interactions with Jynarque.

Common Jynarque Drug Interactions

Drug Name

Risk Level

Description

Desmopressin

Major

The therapeutic efficacy of Desmopressin can be decreased when used in combination with Tolvaptan.

Agmatine

Minor

The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Agmatine.

Aliskiren

Minor

The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Aliskiren.

Alminoprofen

Minor

The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Alminoprofen.

Anisodamine

Minor

The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Anisodamine.

Jynarque Toxicity & Overdose RiskThe lowest toxic dose of tolvaptan in rats and dogs is greater than 2000mg/kg. Common side effects of tolvaptan are feeling thirsty, dry mouth, weakness, constipation, increased urination, and high blood sugar.

image of a doctor in a lab doing drug, clinical research

Jynarque Novel Uses: Which Conditions Have a Clinical Trial Featuring Jynarque?

Currently, 6 active trials are exploring the utility of Jynarque in providing symptomatic relief for euvolemic Hyponatremia, Polycystic Kidney Disease, Autosomal Dominant Polycystic Kidney Disease and symptomatic hypervolemic Hyponatremia.

Condition

Clinical Trials

Trial Phases

Polycystic Kidney, Autosomal Dominant

8 Actively Recruiting

Phase 2, Not Applicable, Phase 3, Phase 1

symptomatic hypervolemic Hyponatremia

0 Actively Recruiting

symptomatic euvolemic Hyponatremia

0 Actively Recruiting

Jynarque Reviews: What are patients saying about Jynarque?

5Patient Review

8/1/2022

Jynarque for Autosomal Dominant Polycystic Kidney Disease

Jynarque has been working great for me. I'm proof that different people can get different results from the same treatment; my kidneys have actually been getting better lately.

1.7Patient Review

11/27/2019

Jynarque for Autosomal Dominant Polycystic Kidney Disease

It's hard to tell if this treatment is effective because the amount of time it requires is so significant. Additionally, the protocol and requirements are very demanding, and my doctor's office has had trouble keeping up with the blood testing schedule. The insurance company is also less than helpful when things go wrong. Overall, I would not recommend this treatment.

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about jynarque

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How effective is Jynarque?

"The relative rate of events related to ADPKD decreased by 13.5% with JYNARQUE. This was driven by effects on worsening kidney function and pain events. In contrast, tolvaptan had no effect on progression of either hypertension or albuminuria."

Answered by AI

What is Jynarque used for?

"This medication is used by those who have autosomal dominant polycystic kidney disease. This disease leads to the growth of fluid-filled sacs, known as cysts, in the kidneys."

Answered by AI

How long do you take Jynarque?

"If you take JYNARQUE® (tolvaptan), it could seriously injure your liver or even kill you. Check with your doctor before starting this medication, and then again 2 and 4 weeks after you start. After that, you should have checkups monthly for 18 months, and then every 3 months after that."

Answered by AI

What are the side effects of Jynarque?

"Increases in thirst and urination (both in volume and frequency), nighttime urination, indigestion, decreased appetite, bloating, dry skin, and rash are all possible symptoms of diabetes."

Answered by AI

Clinical Trials for Jynarque

Have you considered Jynarque clinical trials? We made a collection of clinical trials featuring Jynarque, we think they might fit your search criteria.